tpgs enjoying commercial success & tpm none .
The “commercial success” of TPGS to date appears to be restricted to orally administered drugs, primarily cancer drugs. Phosphagenics isn’t in that space.
You have previously insisted that TPGS
“owns the injectable development space”. Yet neither you nor I have been able to find an example of even one commercialized TPGS injectable. Despite the fact that TPGS has been around for almost 70 years.
Nor, as I recall, have you presented any examples of commercialized transdermal products that use TPGS. Despite the fact that TPGS has been around for almost 70 years.
they (Phosphagenics)
have nothing to contribute over and above other tocopherol phosphate players.
What you have presented as fact is but your opinion about TPM. To be clear, that is the opinion of someone who comes from a stockbroking background (as you have previously stated).
Ross Murdoch has conducted extensive due diligence on TPM. His background is in biotech/pharma and he has a PhD in Clinical Pharmacology *
*Clinical pharmacology is the study of drugs in humans.
It is underpinned by the basic science of pharmacology, with added focus on the application of pharmacological principles and methods in the real world. It has a broad scope, from the discovery of new target molecules, to the effects of drug usage in whole populations.
Clinical pharmacologists are physicians, pharmacists, and scientists whose focus is developing and understanding new drug therapies. Clinical pharmacologists work in a variety of settings in academia, industry and government. In the laboratory setting they study biomarkers, pharmacokinetics, drug metabolism and genetics. In the office setting they design and evaluate clinical trials, create and implement regulation guidelines for drug use, and look at drug utilization on local and global scales. In the clinical setting they work directly with patients, participate in experimental studies, and investigate adverse reactions and interactions.
In
Ross Murdoch’s opinion, TPM is “unique, adaptable and flexible”. In recent months he has stated that the SIAC arbitration ruling on ownership of the TPM propofol formulation patent does not reflect the utility or ongoing value of TPM.
I place more weight on the opinion of Ross Murdoch in this matter.
(20min delay)
